Park Square is pleased to announce the placement of Ferdinand Massari, M.D., as Chief Medical Officer at Deep Genomics. Deep Genomics is a pioneering biotechnology company that leverages artificial intelligence and genome biology to discover and develop life-saving genetic therapies.
Dr. Massari is a seasoned R&D executive who brings a wealth of experience overseeing the discovery, translation, development, and commercialization of novel medicines across a range of therapeutic areas. Most recently, Dr. Massari served as President, R&D at Kintai Therapeutics where he built and scaled the research and development organization. Previously, he was Global Head and Vice President, Clinical and Medical Affairs at Shire Human Genetic Therapies. Prior to this role, Dr. Massari served as Senior Vice President, Drug Development and Chief Medical Officer at Coley Pharmaceuticals, which was acquired by Pfizer. Dr. Massari began his career in roles of increasing responsibility at Merck, Sanofi-Aventis, and Pfizer.
Dr. Massari received his M.D. from Jefferson Medical College and a B.A. in Political Science from the University of Maryland, Baltimore County.
Park Square Executive Search serves companies and institutions that are shaping the world through discovery, innovation and growth. Our clients are leading life sciences and healthcare organizations, technology companies, major research universities, and venture capital and private equity firms, including their portfolio companies. We place board members, chief executive officers, C-suite executives, and academic leaders.